Omada Health Inc. has announced results from a 12-month real-world analysis of its GLP-1 companion program, which supports members using anti-obesity medications, including GLP-1s. The study, an extension of a previous six-month analysis, was conducted as part of the Omada Insights Lab ANSWERS Initiative, which examines real-world data from Omada's weight health programs. According to the announcement, the findings highlight the program's role in assisting employers with the complexities of the weight loss medication market and delivering measurable, long-term value. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omada Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622266) on January 08, 2026, and is solely responsible for the information contained therein.